Table 4 Clinical trials of anti-cancer therapies targeting Axl
From: Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Methods of drug application | Disease type | Phase | Current status | ClinicalTrials.gov identifier |
|---|---|---|---|---|
Bemcentinib (before surgery); Bemcentinib (after surgery) | Brain and central nervous system tumors | 1 | Active | NCT03965494 |
Bemcentinib; docetaxel | Non-small cell lung cancer | 1 | Active | NCT02922777 |
Bemcentinib; pembrolizumab | Triple-negative breast cancer; inflammatory breast cancer stage IV | 2 | Terminated | NCT03184558 |
Bemcentinib; cytarabine; decitabine | Acute myeloid leukemia; myelodysplastic syndromes | 1/2 | Active | NCT02488408 |
Bemcentinib; pembrolizumab | Lung cancer metastatic; NSCLC stage IV; adenocarcinoma of lung | 2 | Completed | NCT03184571 |
Bemcentinib+pembrolizumab; Bemcentinib+dabrafenib and trametinib; pembrolizumab; dabrafenib and trametinib | Melanoma | 1/2 | Active | NCT02872259 |
Erlotinib; bemcentinib | Non-small cell lung cancer | 1/2 | Completed | NCT02424617 |
Bemcentinib | Acute myeloid leukemia; high-risk myelodysplastic syndrome; low-risk myelodysplastic syndrome | 2 | Completed | NCT03824080 |
Rucaparib; abemaciclib; pembrolizumab and bemcentinib | Mesothelioma, malignant | 2 | Active | NCT03654833 |
